Let Activefol.io Invest in BIIB on Your Behalf.
- Active Investing
- Personalized Strategy
- Low Monthly Fees
Course of Action
Sentiment (10 days)
- Strong Buy
- Strong Sell
DAILY PRICE CHANGE VS SENTIMENT
What is Systematic Investing?
Activefol.io is an advanced automated Portfolio Manager designed to provides investors with a state of the art automated investment system to invest in the S&P 500®. Its technology is designed to screen, monitor and invest in elite stocks like "BIOGEN INC. (BIIB)". It's Artificial Intelligence augments your potential for profit while eliminating most of the work traditionally involved in stock investing.
What is Activefol.io good for?
If you are interested in systematic, active investing, Activefol.io can be a great alternative to passive index funds and ETFs. Activefol.io uses Artificial Intelligence concepts to screen, monitor and invest in elite stocks. Used in a tax-deferred account such as IRAs and Roth IRAs, it invests systematically using carefully instrumented strategies. Using Activefol.io is like having a professional Portfolio Manager working for you. You turn it on and it starts working on your behalf.
Activefol.io actively trades the S&P 500®, day-in, and day-out, while you attend more important life events. Because of the systematic nature of Activefol.io, your account has the potential to grow at a faster rate than if you were to use a passive investment product such as an index fund or ETF. Systematic active trading using Artificial Intelligence holds the potential to grow your account faster.
Using Activefol.io is Easy
To connect Activefol.io to your account you will need to open an account with one of our Broker / Dealer partners in the United States. Our Partners offer very competitive services and flawless execution.
There are clear benefits associated with using Activefol.io to help you reach your financial goals. Activefol.io simplifies stock investing down to a few easy steps. It systematically invests for you, using your personalized strategy.
Using Activefol.io is like having a professional Portfolio Manager working for you to help you reach your financial goals.
Activefol.io actively invests which is different from passive investing. Our automated solution is on the lookout, working to maximize your potential every minute of a business day. It 'trades on the news' taking advantage of changes.
Activefol.io is one of the first platforms to take advantage of Government grade listening technology to monitor and classify securities.
Try Activefol.io today!
You can test Activefol.io in simulation mode, risk free, Stock Circles today.
Get started now - and see where active automated trading can take you.
Disclaimer: Past performance may not be indicative of future results. Therefore, you should assume that the future performance of any specific investment and systematic investment strategies will be profitable. Activefol.io, like other investment methods, rely on favorable market conditions to provide positive outcomes.
BIOGEN INC. (BIIB) News
Biogen and Neurimmune Announce Option Exercise for Alzheimer’s Disease Investigational Treatment Aducanumab
Biogen (Nasdaq: BIIB) and Neurimmune announced today that Biogen has exercised its option to further reduce the previously negotiated royalty rates payable on potential future sales of aducanumab, Biogen’s Phase 3 investigational treatment for early Alzheimer’s disease.
Biogen will make a one-time $50 million payment to Neurimmune in exchange for a 5% reduction in the original royalty rates on potential commercial sales of aducanumab, which follows the 15% reduction in royalty rates announced in October 2017. The reduced royalty rates on potential commercial sales of aducanumab will be in the high single digits to low-teens. Biogen licensed the worldwide rights to aducanumab from Neurimmune in 2007.
“Biogen values our collaboration with Neurimmune, and this step is aligned with our amended agreement from 2017,” said Michel Vounatsos, chief executive officer of Biogen. “As we progress our pipeline of candidates for Alzheimer’s disease including aducanumab, we hope that a potential treatment for this devastating and debilitating disease will be realized.”
“At Neurimmune, we are pleased with the continuous progress of our long-term successful collaboration with Biogen,” said Roger Nitsch, chief executive officer of Neurimmune. “This non-dilutive financing supports our growth strategy focused on bringing human-derived antibodies through clinical proof-of-concept in disease areas with high medical need.”Get Started today! - Risk Free